» Articles » PMID: 21377524

Cytokine Involvement in Stress May Depend on Corticotrophin Releasing Factor to Sensitize Ethanol Withdrawal Anxiety

Overview
Publisher Elsevier
Date 2011 Mar 8
PMID 21377524
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Stress has been shown to facilitate ethanol withdrawal-induced anxiety. Defining neurobiological mechanisms through which stress has such actions is important given the associated risk of relapse. While CRF has long been implicated in the action of stress, current results show that stress elevates the cytokine TNFα in the rat brain and thereby implicates cytokines in stress effects. In support of this view, prior TNFα microinjection into the central amygdala (CeA) of rats facilitated ethanol withdrawal-induced anxiety-a response that could not be attributed to an increase in plasma corticosterone. To test for a possible interaction between cytokines and CRF, a CRF1-receptor antagonist (SSR125543) administered prior to the repeated administration of TNFα or MCP-1/CCL2 reduced the magnitude of the withdrawal-induced anxiety. This finding provided evidence for cytokine action being dependent upon CRF. Additionally, the sensitizing effect of stress on withdrawal-induced anxiety was reduced by treating the repeated stress exposure prior to ethanol with the MEK inhibitor SL327. Consistent with cytokines having a neuromediator function distinct from a neuroimmune action, TNFα increased firing rate and GABA release from CeA neurons. Thus, an interaction of glial and neuronal function is proposed to contribute to the interaction of stress and chronic ethanol. Interrupting this potential glial-neuronal interaction could provide a novel means by which to alter the development of emotional states induced by stress that predict relapse in the alcoholic.

Citing Articles

extract attenuates corticotropin-releasing hormone-induced cellular senescence in human hair follicle cells.

Lee S, Kim S, Lee S, Jang S, Hwang S, Kwon Y iScience. 2024; 27(5):109675.

PMID: 38706837 PMC: 11068553. DOI: 10.1016/j.isci.2024.109675.


A reverse translational study of PPAR-α agonist efficacy in human and rodent models relevant to alcohol use disorder.

Mason B, Estey D, Roberts A, de Guglielmo G, George O, Light J Neurobiol Stress. 2024; 29:100604.

PMID: 38292518 PMC: 10825428. DOI: 10.1016/j.ynstr.2023.100604.


Dissecting the Relationship Between Neuropsychiatric and Neurodegenerative Disorders.

Gupta R, Advani D, Yadav D, Ambasta R, Kumar P Mol Neurobiol. 2023; 60(11):6476-6529.

PMID: 37458987 DOI: 10.1007/s12035-023-03502-9.


Stress- and drug-induced neuroimmune signaling as a therapeutic target for comorbid anxiety and substance use disorders.

Smiley C, Wood S Pharmacol Ther. 2022; 239:108212.

PMID: 35580690 PMC: 11154639. DOI: 10.1016/j.pharmthera.2022.108212.


Solitary Nitric Oxide Signaling Mediates Mild Stress-Induced Anxiety and Norepinephrine Release in the Bed Nucleus of the Stria Terminalis during Protracted Ethanol Withdrawal.

Zhao Z, Kim S, Jiao Y, Wang Y, Lee B, Kim H Behav Neurol. 2021; 2021:2149371.

PMID: 34880955 PMC: 8648454. DOI: 10.1155/2021/2149371.


References
1.
Dunn A, Swiergiel A, de Beaurepaire R . Cytokines as mediators of depression: what can we learn from animal studies?. Neurosci Biobehav Rev. 2005; 29(4-5):891-909. DOI: 10.1016/j.neubiorev.2005.03.023. View

2.
Frank M, Miguel Z, Watkins L, Maier S . Prior exposure to glucocorticoids sensitizes the neuroinflammatory and peripheral inflammatory responses to E. coli lipopolysaccharide. Brain Behav Immun. 2009; 24(1):19-30. DOI: 10.1016/j.bbi.2009.07.008. View

3.
Bajetto A, Bonavia R, Barbero S, Schettini G . Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem. 2002; 82(6):1311-29. DOI: 10.1046/j.1471-4159.2002.01091.x. View

4.
Deak T, Bordner K, McElderry N, Barnum C, Blandino Jr P, Deak M . Stress-induced increases in hypothalamic IL-1: a systematic analysis of multiple stressor paradigms. Brain Res Bull. 2005; 64(6):541-56. DOI: 10.1016/j.brainresbull.2004.11.003. View

5.
Lowery E, Thiele T . Pre-clinical evidence that corticotropin-releasing factor (CRF) receptor antagonists are promising targets for pharmacological treatment of alcoholism. CNS Neurol Disord Drug Targets. 2010; 9(1):77-86. PMC: 2853890. DOI: 10.2174/187152710790966605. View